Claims Scope:

Patent issued March 13, 2018.

≥90% Sequence Identity – Compositions only

Composition of a viral vector for treating condition associated with the mevalonate pathway, encoding an shRNA or a microRNA that inhibits the mevalonate pathway, comprising shRNA having at least 90% percent identity to SEQ 1-4, or, microRNA having at least 90% identity to SEQ 5-10.

Lentiviral particle and pharmaceutical composition comprising an envelope protein capable of infecting a cells and a viral vector encoding an shRNA or a microRNA that inhibits the mevalonate pathway, comprising shRNA having at least 90% percent identity to SEQ 1-4, or, microRNA having at least 90% identity to SEQ 5-10

No limitation to activating GD T cells or infecting a cancer cell.